These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 24822060)
41. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability. Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826 [TBL] [Abstract][Full Text] [Related]
42. Clinicopathological and Molecular Profiles of Sporadic Microsatellite Unstable Colorectal Cancer with or without the CpG Island Methylator Phenotype (CIMP). Chang SC; Li AF; Lin PC; Lin CC; Lin HH; Huang SC; Lin CH; Liang WY; Chen WS; Jiang JK; Lin JK; Yang SH; Lan YT Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33238621 [TBL] [Abstract][Full Text] [Related]
43. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer. Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725 [TBL] [Abstract][Full Text] [Related]
44. Clinical Significance of MLH1 Methylation and CpG Island Methylator Phenotype as Prognostic Markers in Patients with Gastric Cancer. Shigeyasu K; Nagasaka T; Mori Y; Yokomichi N; Kawai T; Fuji T; Kimura K; Umeda Y; Kagawa S; Goel A; Fujiwara T PLoS One; 2015; 10(6):e0130409. PubMed ID: 26121593 [TBL] [Abstract][Full Text] [Related]
45. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Chang MS; Uozaki H; Chong JM; Ushiku T; Sakuma K; Ishikawa S; Hino R; Barua RR; Iwasaki Y; Arai K; Fujii H; Nagai H; Fukayama M Clin Cancer Res; 2006 May; 12(10):2995-3002. PubMed ID: 16707594 [TBL] [Abstract][Full Text] [Related]
46. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Abe M; Westermann F; Nakagawara A; Takato T; Schwab M; Ushijima T Cancer Lett; 2007 Mar; 247(2):253-8. PubMed ID: 16759796 [TBL] [Abstract][Full Text] [Related]
48. CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis. Fu T; Pappou EP; Guzzetta AA; Jeschke J; Kwak R; Dave P; Hooker CM; Morgan R; Baylin SB; Iacobuzio-Donahue CA; Wolfgang CL; Ahuja N Clin Cancer Res; 2012 Sep; 18(17):4743-52. PubMed ID: 22825585 [TBL] [Abstract][Full Text] [Related]
49. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Ogino S; Meyerhardt JA; Kawasaki T; Clark JW; Ryan DP; Kulke MH; Enzinger PC; Wolpin BM; Loda M; Fuchs CS Virchows Arch; 2007 May; 450(5):529-37. PubMed ID: 17372756 [TBL] [Abstract][Full Text] [Related]
50. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Ahn JB; Chung WB; Maeda O; Shin SJ; Kim HS; Chung HC; Kim NK; Issa JP Cancer; 2011 May; 117(9):1847-54. PubMed ID: 21509761 [TBL] [Abstract][Full Text] [Related]
51. The role of the CpG island methylator phenotype on survival outcome in colon cancer. Kang KJ; Min BH; Ryu KJ; Kim KM; Chang DK; Kim JJ; Rhee JC; Kim YH Gut Liver; 2015 Mar; 9(2):202-7. PubMed ID: 25167802 [TBL] [Abstract][Full Text] [Related]
52. The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases. Cohen SA; Yu M; Baker K; Redman M; Wu C; Heinzerling TJ; Wirtz RM; Charalambous E; Pentheroudakis G; Kotoula V; Kalogeras KT; Fountzilas G; Grady WM Clin Epigenetics; 2017; 9():46. PubMed ID: 28469732 [TBL] [Abstract][Full Text] [Related]
53. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer. Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946 [TBL] [Abstract][Full Text] [Related]
54. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972 [TBL] [Abstract][Full Text] [Related]
55. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. van Rijnsoever M; Grieu F; Elsaleh H; Joseph D; Iacopetta B Gut; 2002 Dec; 51(6):797-802. PubMed ID: 12427779 [TBL] [Abstract][Full Text] [Related]
56. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. Ogino S; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS J Mol Diagn; 2006 Nov; 8(5):582-8. PubMed ID: 17065427 [TBL] [Abstract][Full Text] [Related]
57. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Toyota M; Ahuja N; Suzuki H; Itoh F; Ohe-Toyota M; Imai K; Baylin SB; Issa JP Cancer Res; 1999 Nov; 59(21):5438-42. PubMed ID: 10554013 [TBL] [Abstract][Full Text] [Related]
58. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype. Bae JM; Kim JH; Kang GH Histol Histopathol; 2013 May; 28(5):585-95. PubMed ID: 23341177 [TBL] [Abstract][Full Text] [Related]
59. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Cheng YW; Pincas H; Bacolod MD; Schemmann G; Giardina SF; Huang J; Barral S; Idrees K; Khan SA; Zeng Z; Rosenberg S; Notterman DA; Ott J; Paty P; Barany F Clin Cancer Res; 2008 Oct; 14(19):6005-13. PubMed ID: 18829479 [TBL] [Abstract][Full Text] [Related]
60. Stratification and Prognostic Relevance of Jass's Molecular Classification of Colorectal Cancer. Zlobec I; Bihl MP; Foerster A; Rufle A; Terracciano L; Lugli A Front Oncol; 2012; 2():7. PubMed ID: 22655257 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]